BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406 AND Treatment
42 results:

  • 1. The bap1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
    Sato H; Ito T; Hayashi T; Kitano S; Erdjument-Bromage H; Bott MJ; Toyooka S; Zauderer M; Ladanyi M
    Oncogene; 2024 Apr; 43(15):1087-1097. PubMed ID: 38383726
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Unveiling the hidden role of disulfidptosis in kidney renal clear cell carcinoma: a prognostic signature for personalized treatment.
    Ye Y; Zeng S; Hu X
    Apoptosis; 2024 Jun; 29(5-6):693-708. PubMed ID: 38296888
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. bap1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
    Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
    Lu X; Vano YA; Su X; Helleux A; Lindner V; Mouawad R; Spano JP; Rouprêt M; Compérat E; Verkarre V; Sun CM; Bennamoun M; Lang H; Barthelemy P; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
    Cell Rep Med; 2023 Nov; 4(11):101287. PubMed ID: 37967556
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report.
    McLoughlin DE; Chevalier N; Choy E; Cote GM; Gao X; Juric D; Reynolds KL
    Oncologist; 2023 Dec; 28(12):1094-1099. PubMed ID: 37844295
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
    Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
    Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.
    Cotta BH; Choueiri TK; Cieslik M; Ghatalia P; Mehra R; Morgan TM; Palapattu GS; Shuch B; Vaishampayan U; Van Allen E; Ari Hakimi A; Salami SS
    Eur Urol; 2023 Aug; 84(2):166-175. PubMed ID: 37085424
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Hereditary renal tumor syndromes.].
    Sánta F; Semjén D; Kuthi L
    Orv Hetil; 2023 Mar; 164(10):363-375. PubMed ID: 36906860
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. treatment Strategies for Hereditary kidney Cancer: Current Recommendations and Updates.
    Singh S; Chaurasia A; Gopal N; Malayeri A; Ball MW
    Discov Med; 2022; 34(173):205-220. PubMed ID: 36602871
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.
    Li Y; Lih TM; Dhanasekaran SM; Mannan R; Chen L; Cieslik M; Wu Y; Lu RJ; Clark DJ; Kołodziejczak I; Hong R; Chen S; Zhao Y; Chugh S; Caravan W; Naser Al Deen N; Hosseini N; Newton CJ; Krug K; Xu Y; Cho KC; Hu Y; Zhang Y; Kumar-Sinha C; Ma W; Calinawan A; Wyczalkowski MA; Wendl MC; Wang Y; Guo S; Zhang C; Le A; Dagar A; Hopkins A; Cho H; Leprevost FDV; Jing X; Teo GC; Liu W; Reimers MA; Pachynski R; Lazar AJ; Chinnaiyan AM; Van Tine BA; Zhang B; Rodland KD; Getz G; Mani DR; Wang P; Chen F; Hostetter G; Thiagarajan M; Linehan WM; Fenyö D; Jewell SD; Omenn GS; Mehra R; Wiznerowicz M; Robles AI; Mesri M; Hiltke T; An E; Rodriguez H; Chan DW; Ricketts CJ; Nesvizhskii AI; Zhang H; Ding L;
    Cancer Cell; 2023 Jan; 41(1):139-163.e17. PubMed ID: 36563681
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.
    Deng Y; Guo K; Tang Z; Feng Y; Cai S; Ye J; Xi Y; Li J; Liu R; Cai C; Tan Z; Zhang Y; Han Z; Zeng G; Zhong W
    Front Immunol; 2022; 13():1046790. PubMed ID: 36505457
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications.
    Langbein LE; El Hajjar R; Kim WY; Yang H
    Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1417-C1429. PubMed ID: 36154696
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma.
    Shi X; Niu Y; Yang Y; Wang N; Yuan M; Yang C; Dong A; Zhu H; Jia X
    Oxid Med Cell Longev; 2022; 2022():1727575. PubMed ID: 36052158
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. bap1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma.
    Langbein LE; El Hajjar R; He S; Sementino E; Zhong Z; Jiang W; Leiby BE; Li L; Uzzo RG; Testa JR; Yang H
    Cancer Lett; 2022 Oct; 547():215885. PubMed ID: 35995140
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Exploring synthetic lethal network for the precision treatment of clear cell renal cell carcinoma.
    Liu Z; Lin D; Zhou Y; Zhang L; Yang C; Guo B; Xia F; Li Y; Chen D; Wang C; Chen Z; Leng C; Xiao Z
    Sci Rep; 2022 Aug; 12(1):13222. PubMed ID: 35918352
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Comprehensive Analysis of Senescence Characteristics Defines a Novel Prognostic Signature to Guide Personalized treatment for Clear Cell Renal Cell Carcinoma.
    Zhou P; Liu Z; Hu H; Lu Y; Xiao J; Wang Y; Xun Y; Xia Q; Liu C; Hu J; Wang S
    Front Immunol; 2022; 13():901671. PubMed ID: 35720278
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Panel of Candidate Genes to Predict the Survival of Patients with Clear Cell Renal Cancer on the Basis of Gene Expression Regulated by HIF1α/HIF2α.
    Apanovich NV; Apanovich PV; Mansorunov DJ; Kuzevanova AY; Korotaeva AA; Bogush TA; Matveev VB; Karpukhin AV
    Bull Exp Biol Med; 2022 Apr; 172(6):738-742. PubMed ID: 35501649
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Bui TO; Dao VT; Nguyen VT; Feugeas JP; Pamoukdjian F; Bousquet G
    Eur Urol; 2022 Apr; 81(4):349-361. PubMed ID: 34991918
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.